Hardingham J E, Kotasek D, Sage R E, Gooley L T, Mi J X, Dobrovic A, Norman J E, Bolton A E, Dale B M
Hematology-Oncology Department, Queen Elizabeth Hospital, Woodville, Australia.
J Clin Oncol. 1995 May;13(5):1073-9. doi: 10.1200/JCO.1995.13.5.1073.
To evaluate the significance of molecular marker-positive cells in a cohort of non-Hodgkin's lymphoma (NHL) patients undergoing high-dose chemotherapy and autologous peripheral-blood stem-cell transplantation (PBSCT).
Twenty-eight PBSC transplants have been performed in 24 patients with poor-prognosis NHL. Molecular analysis of the t(14;18) (q32;q21) translocation (bcl-2/immunoglobulin [Ig] heavy-chain joining locus [JH] fusion) or antigen receptor gene rearrangements was performed to determine the presence of lymphoma cells at presentation, in PBSC harvests, and before and after autologous PBSCT. Kaplan-Meier estimates of survival and Cox regression analyses were used to test the effect of bone marrow involvement, tumor-cell contamination of PBSCs, disease stage, and chemotherapy sensitivity at transplantation, and presence of marker-positive cells post-PBSCT on disease-free and overall survival.
Thirteen of 24 patients (54%) are alive following PBSCT at a median follow-up time of 654 days (range, 193 to 1,908). Nine patients are in complete remission (CR) at day 216 to 1,799 (median, 805) and four are alive following relapse (day 440, 573, 1,188, and 1,908). Eleven patients (46%) have died: three of transplant-related complications at day 0, 1, and 13, and eight of recurrent disease (day 132 to 1,330; median, 451). Longitudinal marker studies post-PBSCT showed that of 16 relapse events, 13 (81%) were positive for the lymphoma marker at or before clinically documented relapse. Marker studies became negative post-PBSCT in nine of nine patients who entered and remained in CR. Disease-free survival (DFS) was significantly shortened in patients in whom marker-positive cells were detected in serial samples posttransplantation (P = .006). Cox regression analysis showed that patients in this group had a 24 times higher risk of relapse (P = .03).
The results show that the reappearance or persistence of marker-positive cells after autologous PBSCT is strongly associated with relapse.
评估分子标志物阳性细胞在接受大剂量化疗及自体外周血干细胞移植(PBSCT)的非霍奇金淋巴瘤(NHL)患者队列中的意义。
对24例预后不良的NHL患者进行了28次PBSC移植。进行了t(14;18)(q32;q21)易位(bcl-2/免疫球蛋白[Ig]重链连接基因座[JH]融合)或抗原受体基因重排的分子分析,以确定初诊时、PBSC采集时、自体PBSCT前后淋巴瘤细胞的存在情况。采用Kaplan-Meier生存估计和Cox回归分析来检验骨髓受累、PBSCs中肿瘤细胞污染、疾病分期、移植时化疗敏感性以及PBSCT后标志物阳性细胞的存在对无病生存和总生存的影响。
24例患者中有13例(54%)在PBSCT后存活,中位随访时间为654天(范围193至1908天)。9例患者在第216至1799天(中位时间805天)达到完全缓解(CR),4例在复发后存活(第440、573、1188和1908天)。11例患者(46%)死亡:3例在第0、1和13天死于移植相关并发症,8例死于复发疾病(第132至1330天;中位时间451天)。PBSCT后的纵向标志物研究显示,在16例复发事件中,13例(81%)在临床记录的复发时或复发前淋巴瘤标志物呈阳性。9例进入并维持CR的患者在PBSCT后标志物研究转为阴性。在移植后系列样本中检测到标志物阳性细胞的患者无病生存(DFS)显著缩短(P = 0.006)。Cox回归分析显示,该组患者复发风险高24倍(P = 0.03)。
结果表明,自体PBSCT后标志物阳性细胞的再现或持续存在与复发密切相关。